Attovia (ATTO) CMO Hubert Receives 140,000-Option Award

What Happened
Chen Hubert, Chief Medical Officer of Attovia Therapeutics (ATTO), was granted an award of 140,000 derivative securities on August 4, 2026. The grant is reported at $0.00 per share (derivative award — options/rights), so no cash changed hands. This is a compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-08-04 (Form 4 filed 2026-08-06). Transaction code: A (award/grant).
• Amount: 140,000 options/rights reported at $0.00 per share.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Vesting (footnote): 25% of the options vest on Aug 4, 2027; the remaining options vest in equal monthly installments over the following 36 months, contingent on continued service.
• Filing timeliness: filed two days after the transaction date (appears timely under the Form 4 two-business-day rule).

Context
This was an equity compensation grant (derivative award) rather than an exercise or sale. It does not indicate an immediate sale or cashless exercise; the options will vest over time subject to continued service. As with most grants, this reflects compensation arrangements for executives and should not be taken alone as a buy/sell signal.